Hypertension in cancer patients

Texas Heart Institute Journal

Volumn 38, Issue 3, 2011, Pages 263-265

  Mouhayar, Elie ^a   Salahudeen, Abdulla ^b  

^a Nephrology Section   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; ANTIHYPERTENSIVE AGENT; CALCINEURIN; SUNITINIB;

ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CANCER CHEMOTHERAPY; CANCER PATIENT; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; PRACTICE GUIDELINE; PREVALENCE; RISK REDUCTION;

ANTINEOPLASTIC AGENTS; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; NEOPLASMS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; STEM CELL TRANSPLANTATION;

EID: 79959945784     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004;291(20):2441-7.
2. Maitland ML, Bakris GL, Black HR, Chen HX, Durand J-B, Elliott WJ, et al. Cardiovascular Toxicities Panel, convened by the Angiogenesis Task Force of the National Cancer Institute Investigational Drug Steering Committee. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010;102(9):596-604.
3. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-34.
4. Meinardi MT, Gietema JA, van der Graaf WT, van Veldhuisen DJ, Runne MA, Sluiter WJ, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000;18(8):1725-32.
5. Bursztyn M, Zelig O, Or R, Nagler A. Isradipine for the prevention of cyclosporine-induced hypertension in allogeneic bone marrow transplant recipients: a randomized, double-blind study. Transplantation 1997;63(7):1034-6.
6. Dhaun N, Webb DJ. Receptor tyrosine kinase inhibition, hypertension, and proteinuria: is endothelin the smoking gun? Hypertension 2010;56(4):575-7.
7. Aparicio-Gallego G, Afonso-Afonso FJ, Leon-Mateos L, Firvida- Perez JL, Vazquez-Estevez S, Lazaro-Quintela M, et al. Molecular basis of hypertension side effects induced by sunitinib. Anticancer Drugs 2011;22(1):1-8.
8. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008;358(11):1129-36.
9. Ketch T, Biaggioni I, Robertson R, Robertson D. Four faces of baroreflex failure: hypertensive crisis, volatile hypertension, orthostatic tachycardia, and malignant vagotonia. Circulation 2002;105(21):2518-23.
10. Rini BI, Cohen DP, Lu D, Chen I, Hariharan ME, Gore RA, et al. Hypertension (HTN) as a biomarker of efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib [abstract]. Poster presented at American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, 2010. Available from: http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=73&abstractID=30099.
11. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JCN 7 report [published erratum appears in JAMA 2003;290(2):197]. JAMA 2003; 289(19):2560-72.
12. Common terminology criteria for adverse events (CTCAE) [publication on the Internet]. Bethesda (MD): U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. NIH publication no. 09- 5410, 2009 May 28 [revised 2010 Jun 14; cited 2011 Mar 31]. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.